Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Dermatology

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 166 articles:
HTML format
Text format



Single Articles


    May 2019
  1. OROUJI E, Federico A, Larribere L, Novak D, et al
    Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
    Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32432.
    PubMed     Text format     Abstract available


    April 2019
  2. ZUR HAUSEN H, Bund T, de Villiers EM
    Specific nutritional infections early in life as risk factors for human colon and breast cancers several decades later.
    Int J Cancer. 2019;144:1574-1583.
    PubMed     Text format    


    February 2019
  3. VERVER D, van der Veldt A, van Akkooi A, Verhoef C, et al
    Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study.
    Int J Cancer. 2019 Feb 23. doi: 10.1002/ijc.32229.
    PubMed     Text format     Abstract available


  4. MIO C, Gerratana L, Bolis M, Caponnetto F, et al
    BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Int J Cancer. 2019;144:755-766.
    PubMed     Text format     Abstract available


  5. KIENY A, Cribier B, Meyer N, Velten M, et al
    Epidemiology of Merkel cell carcinoma. A population-based study from 1985 to 2013, in northeastern of France.
    Int J Cancer. 2019;144:741-745.
    PubMed     Text format     Abstract available


  6. ALTANEROVA U, Jakubechova J, Benejova K, Priscakova P, et al
    Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes.
    Int J Cancer. 2019;144:897-908.
    PubMed     Text format     Abstract available


  7. DAI W, Liu H, Xu X, Jie G, et al
    Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival.
    Int J Cancer. 2019 Feb 8. doi: 10.1002/ijc.32194.
    PubMed     Text format     Abstract available


    January 2019
  8. FRANKE V, Berger DMS, Klop WMC, van der Hiel B, et al
    High Response Rates for T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a).
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32172.
    PubMed     Text format     Abstract available


  9. CERVENKA I, Al Rahmoun M, Mahamat Saleh Y, Savoye I, et al
    Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32150.
    PubMed     Text format     Abstract available


  10. CAHOON EK, Engels EA
    "Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997-2016" Reply to Letter re: Risk of Kaposi sarcoma after solid organ transplantation in the United States.
    Int J Cancer. 2019 Jan 6. doi: 10.1002/ijc.32096.
    PubMed     Text format    


  11. PISELLI P, Taborelli M, Cimaglia C, Serraino D, et al
    Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997-2016.
    Int J Cancer. 2019 Jan 6. doi: 10.1002/ijc.32098.
    PubMed     Text format    


    December 2018
  12. WEIDELE K, Stojanovic N, Feliciello G, Markiewicz A, et al
    Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32092.
    PubMed     Text format     Abstract available


  13. GUO D, Lui GYL, Lai SL, Wilmott JS, et al
    RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.
    Int J Cancer. 2018 Dec 17. doi: 10.1002/ijc.32064.
    PubMed     Text format     Abstract available


  14. POLLOM EL, Qian Y, Chin AL, Dirbas FM, et al
    Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy.
    Int J Cancer. 2018;143:3262-3272.
    PubMed     Text format     Abstract available


  15. HAMERS FF, Assogba FAG, Rogel A
    Implementation and organization of cancer screening in France.
    Int J Cancer. 2018;143:3281.
    PubMed     Text format    


  16. GRAF ME, Sookthai D, Johnson T, Schubel R, et al
    Pre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study.
    Int J Cancer. 2018;143:2659-2667.
    PubMed     Text format     Abstract available


  17. MIGLIO U, Berrino E, Panero M, Ferrero G, et al
    The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers.
    Int J Cancer. 2018;143:2838-2848.
    PubMed     Text format     Abstract available


    November 2018
  18. KLASCHIK K, Hauke J, Neidhardt G, Trankle C, et al
    The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32016.
    PubMed     Text format    


  19. BULANOVA DR, Helenius M, Sokolenko AP, Kuznetsov SG, et al
    Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32013.
    PubMed     Text format    


  20. RUEEGG CS, Stenehjem JS, Egger M, Ghiasvand R, et al
    Challenges in Assessing the Sunscreen-Melanoma Association.
    Int J Cancer. 2018 Nov 16. doi: 10.1002/ijc.31997.
    PubMed     Text format     Abstract available


  21. SROUR B, Plancoulaine S, Andreeva VA, Fassier P, et al
    Circadian nutritional behaviours and cancer risk: New insights from the NutriNet-sante prospective cohort study: Disclaimers.
    Int J Cancer. 2018;143:2369-2379.
    PubMed     Text format     Abstract available


  22. POTJER TP, Bollen S, Grimbergen AJEM, van Doorn R, et al
    Multi-gene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Int J Cancer. 2018 Nov 10. doi: 10.1002/ijc.31984.
    PubMed     Text format     Abstract available


    October 2018
  23. VAN MAAREN MC, de Munck L, Strobbe LJ, Sonke GS, et al
    10-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.
    Int J Cancer. 2018 Oct 28. doi: 10.1002/ijc.31914.
    PubMed     Text format     Abstract available


  24. JOHANSSON ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, et al
    Breast cancer-specific survival by clinical subtype after seven years follow-up of young and elderly women in a nationwide cohort.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31950.
    PubMed     Text format     Abstract available


  25. BENS A, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Non-aspirin NSAIDs and contralateral breast cancer risk.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31949.
    PubMed     Text format    


  26. SHEN Y, Zhang W, Liu J, He J, et al
    Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31915.
    PubMed     Text format     Abstract available


  27. LATTOUF H, Kassem L, Jacquemetton J, Choucair A, et al
    LKB1 regulates PRMT5 activity in breast cancer.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31909.
    PubMed     Text format     Abstract available


    September 2018
  28. HARDING C, Pompei F, Burmistrov D, Wilson R, et al
    Long-term relationships between screening rates, breast cancer characteristics, and overdiagnosis in US counties, 1975-2009.
    Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31904.
    PubMed     Text format     Abstract available


  29. DASSLER-PLENKER J, Paschen A, Putschli B, Rattay S, et al
    Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity towards autologous melanoma cells.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31874.
    PubMed     Text format     Abstract available


  30. STROHSNITTER WC, Bertrand KA, Troisi R, Scott CG, et al
    Prenatal diethylstilbestrol exposure and mammographic density.
    Int J Cancer. 2018;143:1374-1378.
    PubMed     Text format     Abstract available


  31. LIN MC, Chen SY, He PL, Herschman H, et al
    PGE2 /EP4 antagonism enhances tumor chemosensitivity by inducing extracellular vesicle-mediated clearance of cancer stem cells.
    Int J Cancer. 2018;143:1440-1455.
    PubMed     Text format     Abstract available


  32. EL-MALLAWANY NK, Mehta PS, Kamiyango W, Villiera J, et al
    KSHV Viral Load and Interleukin-6 in HIV-Associated Pediatric Kaposi Sarcoma-Exploring the Role of Lytic Activation in Driving the Unique Clinical Features Seen in Endemic Regions.
    Int J Cancer. 2018 Sep 11. doi: 10.1002/ijc.31863.
    PubMed     Text format     Abstract available


  33. HAM SA, Kim E, Yoo T, Lee WJ, et al
    Ligand-activated interaction of PPARdelta with c-Myc governs the tumorigenicity of breast cancer.
    Int J Cancer. 2018 Sep 11. doi: 10.1002/ijc.31864.
    PubMed     Text format     Abstract available


  34. KOMEMI O, Epstein Shochet G, Pomeranz M, Fishman A, et al
    Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31861.
    PubMed     Text format     Abstract available


  35. BRADBURY KE, Appleby PN, Tipper SJ, Travis RC, et al
    Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31854.
    PubMed     Text format     Abstract available


  36. JIN ML, Kim YW, Jin HL, Kang H, et al
    Aberrant expression of SETD1A promotes survival and migration of estrogen receptor alpha-positive breast cancer cells.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31853.
    PubMed     Text format     Abstract available


  37. FARVID MS, Stern MC, Norat T, Sasazuki S, et al
    Consumption of red and processed meat and breast cancer incidence: a systematic review and meta-analysis of prospective studies.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31848.
    PubMed     Text format     Abstract available


  38. FALK RT, Manson JE, Barnabei VM, Anderson GL, et al
    Estrogen metabolism in menopausal hormone users in the Women's Health Initiative Observational Study: Does it differ between estrogen plus progestin and estrogen alone?
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31851.
    PubMed     Text format     Abstract available


  39. WILMOTT JS, Johansson PA, Newell F, Waddell N, et al
    Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.
    Int J Cancer. 2018 Sep 4. doi: 10.1002/ijc.31791.
    PubMed     Text format     Abstract available


  40. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Text format     Abstract available


    August 2018
  41. YE L, Li F, Song Y, Yu D, et al
    Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of Triple-Negative Breast Cancer.
    Int J Cancer. 2018 Aug 27. doi: 10.1002/ijc.31766.
    PubMed     Text format     Abstract available


  42. MOLLER MH, Lousdal ML, Kristiansen IS, Stovring H, et al
    Effect of organised mammography screening on breast cancer mortality: A population-based cohort study in Norway.
    Int J Cancer. 2018 Aug 25. doi: 10.1002/ijc.31832.
    PubMed     Text format     Abstract available


  43. ZHAO B, Zhao H, Zhao J
    Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31813.
    PubMed     Text format     Abstract available


  44. GAUDET MM, Deubler EL, Kelly RS, Diver WR, et al
    Blood Levels of Cadmium and Lead in Relation to Breast Cancer Risk in Three Prospective Cohorts.
    Int J Cancer. 2018 Aug 17. doi: 10.1002/ijc.31805.
    PubMed     Text format     Abstract available


  45. WU H, Larribere L, Sun Q, Novak D, et al
    Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31799.
    PubMed     Text format     Abstract available


  46. MC MENAMIN UC, Kunzmann AT, Cook MB, Johnston BT, et al
    Hormonal and reproductive factors and risk of upper gastrointestinal cancers in men: A prospective cohort study within the UK Biobank.
    Int J Cancer. 2018;143:831-841.
    PubMed     Text format     Abstract available


  47. KIVES Z, Juhasz K, Csakvari T, Agoston I, et al
    Cancer screening policy in Hungary.
    Int J Cancer. 2018;143:1003-1004.
    PubMed     Text format    


  48. PEDERSEN MH, Hood BL, Ehmsen S, Beck HC, et al
    CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31798.
    PubMed     Text format     Abstract available


  49. SHARBI-YUNGER A, Grees M, Gal C, Bassan D, et al
    A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Int J Cancer. 2018 Aug 14. doi: 10.1002/ijc.31795.
    PubMed     Text format     Abstract available


  50. LEE WH, Chen LC, Lee CJ, Huang CC, et al
    DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint.
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31788.
    PubMed     Text format     Abstract available


  51. CORTESI L, Canossi B, Battista R, Pecchi A, et al
    Breast ultrasonography in the screening protocol for women at hereditary- familial risk of breast cancer: Has the time come to rethink the role of BU according to different risk categories?
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31794.
    PubMed     Text format     Abstract available


  52. ANDRES-LENCINA JJ, Rachakonda S, Garcia-Casado Z, Srinivas N, et al
    TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31780.
    PubMed     Text format     Abstract available


  53. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
    Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
    PubMed     Text format     Abstract available


  54. KWOK ZH, Roche V, Chew XH, Fadieieva A, et al
    A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers.
    Int J Cancer. 2018;143:668-678.
    PubMed     Text format     Abstract available


  55. OH H, Pfeiffer RM, Falk RT, Horne HN, et al
    Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank.
    Int J Cancer. 2018;143:496-507.
    PubMed     Text format     Abstract available


    July 2018
  56. KOGEVINAS M, Espinosa A, Castello A, Gomez-Acebo I, et al
    Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study).
    Int J Cancer. 2018 Jul 17. doi: 10.1002/ijc.31649.
    PubMed     Text format     Abstract available


  57. ANDREE KC, Mentink A, Zeune LL, Terstappen LWMM, et al
    Towards a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multi-center study (CTCTrap).
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31752.
    PubMed     Text format     Abstract available


  58. BASU P, Selmouni F, Belakhel L, Sauvaget C, et al
    Breast Cancer Screening Program in Morocco: Status of implementation, organization and performance.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31749.
    PubMed     Text format     Abstract available


  59. IZRAELY S, Ben-Menachem S, Sagi-Assif O, Telerman A, et al
    The Metastatic Microenvironment: Melanoma-Microglia Cross-Talk Promotes the Malignant Phenotype of Melanoma Cells.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31745.
    PubMed     Text format     Abstract available


  60. MCCORMACK V, Febvey-Combes O, Ginsburg O, Dos-Santos-Silva I, et al
    Breast cancer in women living with HIV: A first global estimate.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31722.
    PubMed     Text format     Abstract available


  61. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
    Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
    PubMed     Text format    


  62. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
    Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
    PubMed     Text format     Abstract available


  63. CAHOON EK, Linet MS, Clarke CA, Pawlish KS, et al
    Risk of Kaposi sarcoma after solid organ transplantation in the United States.
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31735.
    PubMed     Text format     Abstract available


  64. STERNBERG C, Gruber W, Eberl M, Tesanovic S, et al
    Synergistic Cross-Talk of Hedgehog and Interleukin-6 Signaling Drives Growth of Basal Cell Carcinoma.
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31724.
    PubMed     Text format     Abstract available


  65. BLUMENFELD Z
    Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
    PubMed     Text format    


  66. YANG CC, Chang CK, Chang MT, Shyur LF, et al
    Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-alpha-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31663.
    PubMed     Text format     Abstract available


  67. CERVENKA I, Mahamat-Saleh Y, Savoye I, Dartois L, et al
    Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31644.
    PubMed     Text format     Abstract available


  68. LAN B, Ma F, Chen S, Wang W, et al
    Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10 T/T genotype breast cancer patients in China.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31639.
    PubMed     Text format     Abstract available


  69. PARK YH, Lee KH, Sohn JH, Lee KS, et al
    A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31651.
    PubMed     Text format     Abstract available


  70. VANGANGELT KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, et al
    The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31658.
    PubMed     Text format     Abstract available


  71. SALEM Y, Yacov N, Propheta-Meiran O, Breitbart E, et al
    Newly Characterized Motile Sperm Domain-Containing Protein 2 Promotes Human Breast Cancer Metastasis.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31665.
    PubMed     Text format     Abstract available


  72. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Text format     Abstract available


  73. KISO M, Tanaka S, Saji S, Toi M, et al
    Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31645.
    PubMed     Text format     Abstract available


  74. TAN J, Fu L, Chen H, Guan J, et al
    Association study of genetic variation in the autophagy lysosome pathway genes and risk of eight kinds of cancers.
    Int J Cancer. 2018;143:80-87.
    PubMed     Text format     Abstract available


    June 2018
  75. HUSER L, Sachindra, Granados K, Federico A, et al
    SOX2-mediated upregulation of CD24 promotes adaptive resistance towards targeted therapy in melanoma.
    Int J Cancer. 2018 Jun 15. doi: 10.1002/ijc.31609.
    PubMed     Text format     Abstract available


    May 2018
  76. WU W, Chen F, Cui X, Yang L, et al
    LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
    Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
    PubMed     Text format     Abstract available


  77. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Text format     Abstract available


  78. XIE J, Shen K, Lenchine RV, Gethings LA, et al
    Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
    Int J Cancer. 2018;142:1865-1877.
    PubMed     Text format     Abstract available


    April 2018
  79. LI J, Wang W, Xia P, Wan L, et al
    Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in breast cancer patients.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31573.
    PubMed     Text format     Abstract available


  80. AL-AWADHI A, Murray JL, Ibrahim NK
    Developing Anti-HER2 Vaccines: Breast Cancer Experience.
    Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31551.
    PubMed     Text format     Abstract available


  81. ARNOLD M, de Vries E, Whiteman DC, Jemal A, et al
    Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31527.
    PubMed     Text format     Abstract available


  82. WILKE CM, Braselmann H, Hess J, Klymenko SV, et al
    A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31533.
    PubMed     Text format     Abstract available


  83. BOCK J, Appenzeller S, Haertle L, Schneider T, et al
    Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31526.
    PubMed     Text format     Abstract available


  84. SHAFIEE A, McGovern JA, Lahr CA, Meinert C, et al
    Immune System Augmentation via Humanization Using Stem/Progenitor Cells and Bioengineering in a Breast Cancer Model Study.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31528.
    PubMed     Text format     Abstract available


  85. CAO C, Wu H, Vasilatos SN, Chandran U, et al
    HDAC5-LSD1 Axis Regulates Antineoplastic Effect of Natural HDAC Inhibitor Sulforaphane in Human Breast Cancer Cells.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31419.
    PubMed     Text format     Abstract available


  86. NJOR SH, Paci E, Rebolj M
    As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31420.
    PubMed     Text format     Abstract available


    March 2018
  87. ERIKSSON L, Bergh J, Humphreys K, Warnberg F, et al
    Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31411.
    PubMed     Text format     Abstract available


  88. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Text format     Abstract available


  89. DE MUNCK L, Fracheboud J, de Bock GH, den Heeten GJ, et al
    Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31388.
    PubMed     Text format     Abstract available


  90. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Text format     Abstract available


  91. WEI F, Li M, Wu X, Yin K, et al
    The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: A population-based study.
    Int J Cancer. 2018;142:1244-1251.
    PubMed     Text format     Abstract available


  92. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Text format     Abstract available


  93. ABUBAKAR M, Chang-Claude J, Ali HR, Chatterjee N, et al
    Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31352.
    PubMed     Text format     Abstract available


    February 2018
  94. CZARNECKI D
    Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31348.
    PubMed     Text format    


  95. AITKEN JF, Youlden DR, Baade PD, Soyer HP, et al
    In response to: Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31347.
    PubMed     Text format    


  96. LIYANAGE UE, Law MH, Ong JS, Cust AE, et al
    Polyunsaturated fatty acids and risk of melanoma: A Mendelian randomisation analysis.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31334.
    PubMed     Text format     Abstract available


  97. TER VEER E, Creemers A, de Waal L, van Oijen MGH, et al
    Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31325.
    PubMed     Text format     Abstract available


  98. LAN B, Ma F, Zhai X, Li Q, et al
    The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Int J Cancer. 2018 Feb 3. doi: 10.1002/ijc.31291.
    PubMed     Text format     Abstract available


    January 2018
  99. SETTE G, Salvati V, Giordani I, Pillozzi E, et al
    Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31260.
    PubMed     Text format     Abstract available


  100. BEGG CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, et al
    Contralateral breast cancers: Independent cancers or metastases?
    Int J Cancer. 2018;142:347-356.
    PubMed     Text format     Abstract available


  101. LI B, Wang Y, Xu Y, Liu H, et al
    Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival.
    Int J Cancer. 2018 Jan 4. doi: 10.1002/ijc.31243.
    PubMed     Text format     Abstract available


  102. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Text format     Abstract available


    December 2017
  103. ANDERSON C, Engel SM, Anders CK, Nichols HB, et al
    Live birth outcomes after adolescent and young adult breast cancer.
    Int J Cancer. 2017 Dec 21. doi: 10.1002/ijc.31227.
    PubMed     Text format     Abstract available


  104. MARTIN CA, Cullinane C, Kirby L, Abuhammad S, et al
    Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance.
    Int J Cancer. 2017 Dec 15. doi: 10.1002/ijc.31220.
    PubMed     Text format     Abstract available


  105. CHEN J, Yao Q, Huang M, Wang B, et al
    A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients with Breast Cancer (CBCRT01).
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31217.
    PubMed     Text format     Abstract available


  106. XIE X, Tan W, Chen B, Huang X, et al
    Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31208.
    PubMed     Text format     Abstract available


  107. MA L, Fu Q, Xu B, Zhou H, et al
    Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31207.
    PubMed     Text format     Abstract available


  108. GALLAGHER SJ, Gunatilake D, Beaumont KA, Sharp DM, et al
    HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31199.
    PubMed     Text format     Abstract available


  109. HUANG L, Qin Y, Zuo Q, Bhatnagar K, et al
    Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31196.
    PubMed     Text format     Abstract available


  110. UGGE H, Udumyan R, Carlsson J, Andren O, et al
    Acne in late adolescence and risk of prostate cancer.
    Int J Cancer. 2017 Dec 4. doi: 10.1002/ijc.31192.
    PubMed     Text format     Abstract available


  111. DALLASPEZIA S, Cantamessa S, Benedetti F
    Light Therapy and Mood in Breast Cancer.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31188.
    PubMed     Text format    


  112. MCKENZIE F, Zietsman A, Galukande M, Anele A, et al
    Drivers of advanced stage at breast cancer diagnosis in the multi-country African Breast Cancer - Disparities in Outcomes (ABC-DO) study.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31187.
    PubMed     Text format     Abstract available


    November 2017
  113. LEE KR, Hwang IC, Do Han K, Jung J, et al
    Waist circumference and risk of breast cancer in Korean women: A nationwide cohort study.
    Int J Cancer. 2017 Nov 29. doi: 10.1002/ijc.31180.
    PubMed     Text format     Abstract available


  114. HIS M, Le Guelennec M, Mesrine S, Boutron-Ruault MC, et al
    Life course evolution of body size and breast cancer survival in the E3N cohort.
    Int J Cancer. 2017 Nov 27. doi: 10.1002/ijc.31177.
    PubMed     Text format     Abstract available


  115. CHEN ST, Li X, Han J
    Personal history of non-melanoma skin cancer diagnosis and death from melanoma in women.
    Int J Cancer. 2017 Nov 24. doi: 10.1002/ijc.31176.
    PubMed     Text format     Abstract available


  116. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
    Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
    Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
    PubMed     Text format     Abstract available


  117. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Reply to prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 20. doi: 10.1002/ijc.31162.
    PubMed     Text format    


  118. KAWADA T
    Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 18. doi: 10.1002/ijc.31163.
    PubMed     Text format    


  119. SCHAIRER C, Pfeiffer RM, Gadalla SM
    Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
    Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
    PubMed     Text format     Abstract available


  120. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
    Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
    PubMed     Text format     Abstract available


  121. WANG Y, Pfeiffer RM, Alsaggaf R, Meeraus W, et al
    Risk of skin cancer among patients with myotonic dystrophy type 1 based on Primary care physician data from the United Kingdom Clinical Practice Research Datalink.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31143.
    PubMed     Text format     Abstract available


  122. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Text format     Abstract available


  123. AITKEN JF, Youlden DR, Baade PD, Soyer HP, et al
    Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014.
    Int J Cancer. 2017 Nov 6. doi: 10.1002/ijc.31141.
    PubMed     Text format     Abstract available


    October 2017
  124. SCHMIDT ME, Wiskemann J, Schneeweiss A, Potthoff K, et al
    Determinants of physical, affective, and cognitive fatigue: During breast cancer therapy and 12 months follow-up.
    Int J Cancer. 2017 Oct 30. doi: 10.1002/ijc.31138.
    PubMed     Text format     Abstract available


  125. HIRKO KA, Chai B, Spiegelman D, Campos H, et al
    Erythrocyte membrane fatty acids and breast cancer risk: A prospective analysis in the Nurses' Health Study II.
    Int J Cancer. 2017 Oct 26. doi: 10.1002/ijc.31133.
    PubMed     Text format     Abstract available


  126. KEINAN-BOKER L, Levine H, Leiba A, Derazne E, et al
    Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31121.
    PubMed     Text format     Abstract available


  127. YU J, Wang X, Lu Q, Wang J, et al
    Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31112.
    PubMed     Text format     Abstract available


  128. SUROWY H, Varga D, Burwinkel B, Marme F, et al
    A low frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31105.
    PubMed     Text format     Abstract available


  129. JACKLYN G, Howard K, Irwig L, Houssami N, et al
    Impact of extending screening mammography to older women Information to support informed choices.
    Int J Cancer. 2017;141:1540-1550.
    PubMed     Text format     Abstract available


  130. ZHAO B, Zhao H
    Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31097.
    PubMed     Text format     Abstract available


  131. CONRAD C, Gotte M, Schlomann U, Roessler M, et al
    ADAM8 expression in breast cancer derived metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
    Int J Cancer. 2017 Oct 7. doi: 10.1002/ijc.31090.
    PubMed     Text format     Abstract available


  132. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and cutaneous melanoma: Prospective data from the population-based Janus Cohort.
    Int J Cancer. 2017 Oct 6. doi: 10.1002/ijc.31086.
    PubMed     Text format     Abstract available


  133. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
    Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
    PubMed     Text format     Abstract available


  134. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Text format     Abstract available


    September 2017
  135. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Sentinel Lymph Node Biopsy vs Observation in Thick Melanoma: A Multicenter Propensity Score Matching Study.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31078.
    PubMed     Text format     Abstract available


  136. THAPA B, Bahadur Kc R, Uludag H
    Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31079.
    PubMed     Text format     Abstract available


  137. GABELLINI C, Gomez-Abenza E, Ibanez-Molero S, Tupone MG, et al
    Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model.
    Int J Cancer. 2017 Sep 26. doi: 10.1002/ijc.31075.
    PubMed     Text format     Abstract available


  138. WILKE CM, Hess J, Klymenko SV, Chumak VV, et al
    Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31072.
    PubMed     Text format     Abstract available


  139. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    PubMed     Text format     Abstract available


  140. KIMBUNG S, Markholm I, Bjohle J, Lekberg T, et al
    Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the phase 2 PROMIX trial.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31070.
    PubMed     Text format     Abstract available


  141. WANG S, Huo D, Kupfer S, Alleyne D, et al
    Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium.
    Int J Cancer. 2017 Sep 10. doi: 10.1002/ijc.31038.
    PubMed     Text format     Abstract available


  142. LAGENDIJK M, van Maaren MC, Saadatmand S, Strobbe LJ, et al
    Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients.
    Int J Cancer. 2017 Sep 7. doi: 10.1002/ijc.31034.
    PubMed     Text format     Abstract available


    August 2017
  143. BERTRAND KA, Gerlovin H, Bethea TN, Palmer JR, et al
    Pubertal growth and adult height in relation to breast cancer risk in African American women.
    Int J Cancer. 2017 Aug 28. doi: 10.1002/ijc.31019.
    PubMed     Text format     Abstract available


  144. WU AH, Vigen C, Butler LM, Tseng CC, et al
    Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans.
    Int J Cancer. 2017 Aug 26. doi: 10.1002/ijc.31018.
    PubMed     Text format     Abstract available


  145. CESPEDES FELICIANO EM, Prentice RL, Aragaki AK, Neuhouser ML, et al
    Methodological Considerations for Disentangling a Risk Factor's Influence on Disease Incidence versus Post-Diagnosis Survival: The Example of Obesity and Breast and Colorectal Cancer Mortality in the Women's Health Initiative.
    Int J Cancer. 2017 Aug 18. doi: 10.1002/ijc.30931.
    PubMed     Text format     Abstract available


  146. ZHENG G, Yu H, Hemminki A, Forsti A, et al
    Familial associations of female breast cancer with other cancers.
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30927.
    PubMed     Text format     Abstract available


  147. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    PubMed     Text format     Abstract available


  148. WHITE AJ, Weinberg CR, Park YM, D'Aloisio AA, et al
    Sleep characteristics, light at night and breast cancer risk in a prospective cohort.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30920.
    PubMed     Text format     Abstract available


    July 2017
  149. NILENDU P, Kumar A, Kumar A, Pal JK, et al
    Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30898.
    PubMed     Text format     Abstract available


  150. SANDSVEDEN M, Manjer J
    Selenium and breast cancer risk: A prospective nested case-control study on serum selenium levels, smoking habits and overweight.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30875.
    PubMed     Text format     Abstract available


  151. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ, et al
    Reply to Letter to Editor: 'Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.'
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30873.
    PubMed     Text format    


  152. AUTIER P, Boniol M
    Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30874.
    PubMed     Text format    


  153. SCHIROSI L, De Summa S, Tommasi S, Paradiso A, et al
    VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30868.
    PubMed     Text format     Abstract available


  154. BARRDAHL M, Rudolph A, Hopper JL, Southey MC, et al
    Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30859.
    PubMed     Text format     Abstract available


    June 2017
  155. FELLER A, Schmidlin K, Bordoni A, Bouchardy C, et al
    Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: A Swiss population-based study.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30856.
    PubMed     Text format     Abstract available


  156. ALMOZYAN S, Colak D, Mansour F, Alaiya A, et al
    PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
    Int J Cancer. 2017 Jun 14. doi: 10.1002/ijc.30834.
    PubMed     Text format     Abstract available


    May 2017
  157. KNIGHT JA, Fan J, Malone KE, John EM, et al
    Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE Study.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30791.
    PubMed     Text format     Abstract available


  158. VAN DEN ENDE C, Oordt-Speets AM, Vroling H, van Agt HME, et al
    Benefits and harms of breast cancer screening with mammography in women aged 40-49 years: A systematic review.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30794.
    PubMed     Text format     Abstract available


  159. LOLAS HAMAMEH S, Renbaum P, Kamal L, Dweik D, et al
    Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30771.
    PubMed     Text format     Abstract available


  160. BEAU AB, Lynge E, Njor SH, Vejborg I, et al
    Benefit-to-harm ratio of the Danish breast cancer screening programme.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30758.
    PubMed     Text format     Abstract available


    April 2017
  161. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, et al
    The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.
    Int J Cancer. 2017 Apr 29. doi: 10.1002/ijc.30754.
    PubMed     Text format     Abstract available


  162. NARKHEDE AA, Shevde LA, Rao SS
    Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30748.
    PubMed     Text format     Abstract available


    March 2017
  163. MARTINEZ VG, Crown J, Porter RK, O'Driscoll L, et al
    Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30705.
    PubMed     Text format     Abstract available


  164. YANG Z, Hackshaw A, Feng Q, Fu X, et al
    Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Int J Cancer. 2017 Mar 14. doi: 10.1002/ijc.30691.
    PubMed     Text format     Abstract available


  165. BRINTON LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, et al
    Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
    Int J Cancer. 2017 Mar 13. doi: 10.1002/ijc.30688.
    PubMed     Text format     Abstract available


  166. PARK YM, White AJ, Nichols HB, O'Brien KM, et al
    The association between metabolic health, obesity phenotype and the risk of breast cancer.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30684.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: